substitute Sequence Listing. Applicant also has amended Claims 3, 7, 16, 18, 21, and 23 to remove redundant language, in accordance with the Examiner's suggestion, and has cancelled nonelected Claims 2, 6, 8-13, 15, 17, 20, 22, 25-27, and 29-32 without prejudice. The amendments to the specification and Claims 3, 7, 16, 18, 21, and 23 are supported by the application as originally filed, and do not introduce new material. Accordingly, entry of the amendments to the specification and Claims 3, 7, 16, 18, 21, and 23 is respectfully requested.

Compliance with Sequence Rules

In the June 14, 2001 Office Action, the Examiner indicated that the application did not comply with the Sequence Rules. In response thereto, applicant attaches herewith Exhibit A, consisting of pages 1-4 of the substitute Sequence Listing. Also enclosed is a substitute computer-readable form containing the substitute Sequence Listing (Exhibit B). Additionally, the specification has been amended to contain the correct sequence identifiers, as required by the Sequence Rules.

The undersigned attorney hereby certifies that the information recorded in computer-readable form is identical to the written Sequence Listing, is supported by the application as filed, and does not introduce new matter into the application as filed. In view of the above-noted amendments and these remarks, applicant respectfully submits that he has complied with the Sequence Rules. Accordingly, entry of the substitute Sequence Listing is respectfully requested.

[illegible]

authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 697-5995

Dated: July 12, 2001
New York, New York

By: _____
Craig J. Arnold
Reg. No. 34,287

SCHEDULE A

REDLINED VERSION

In the Specification:

Please replace the paragraph at page 29, line 16 as follows:

Degenerate primers were made which corresponded to the protein sequence deduced above. These were 5'GC(N)TC(N)GA(AG)CT(N)CT(N)GA(AG) 3' (SEQ ID NO:3) and 5'TT(TC)AT(N)TC(N)TC(N)TC(N)GT(N)GG(N)3' (SEQ ID NO:4). These primers were used to amplify a cDNA made from ΔSCIP Schwann cells, and a ~1.1 kb product was generated. The PCR condition were 94°C for 1 minute, followed by 40 cycles of 94°C for 30 second, 54°C for 3 minutes and 72°C for 1 minute, followed by 72°C for 5 minutes. The PCR product was the cloned using a TA cloning kit (Invitrogen), and sequenced. The cloned OPA1 fragment was then used to screen a mouse brain library (Stratagene) and a human fetal brain library (Clontech). All cloning was done as described (Weinstein *et al.*, 1991), except the probe was generated by random priming instead of nick translation. All sequencing was carried out by automated sequencing on an ABI 310 automated sequencer.

In the Claims:

Please rewrite Claims 3, 7, 16, 18, 21, and 23 as follows:

3. (twice amended) The isolated nucleic acid of Claim 1 comprising the

7. (twice amended) An isolated nucleic acid that hybridizes under high stringency conditions to a nucleic acid that is complementary to the nucleotide sequence of ~~Figure 2B~~ SEQ ID NO:2 or a contiguous fragment thereof, wherein said isolated nucleic acid encodes a protein having the biological activity of Opa1.

16. (twice amended) The vector of Claim 14, wherein the nucleic acid comprises the nucleotide sequence of nucleotides 880-1680 of ~~Figure 2B~~ SEQ ID NO:2.

18. The vector of Claim 14, wherein the nucleic acid hybridizes under high stringency conditions to a nucleic acid that is complementary to the nucleotide sequence of ~~Figure 2B~~ SEQ ID NO:2 or a contiguous fragment thereof.

21. (twice amended) The host cell of Claim 19, wherein the nucleic acid comprises the nucleotide sequence of nucleotides 880-1680 of ~~Figure 2B~~ SEQ ID NO:2.

23. (twice amended) The host cell of Claim 19, wherein the nucleic acid hybridizes under high stringency conditions to a nucleic acid that is complementary to the nucleotide sequence of ~~Figure 2B~~ SEQ ID NO:2 or a contiguous fragment thereof.